###begin article-title 0
###xml 108 111 108 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE</italic>
Lack of significant association of an insertion/deletion polymorphism in the angiotensin converting enzyme (ACE) gene with tropical calcific pancreatitis
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 148 154 148 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1</italic>
###xml 179 186 179 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1 </italic>
###xml 515 518 515 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE</italic>
###xml 622 626 622 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 722 729 722 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1 </italic>
###xml 815 819 815 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 230 238 <span type="species:ncbi:9606">patients</span>
###xml 676 684 <span type="species:ncbi:9606">patients</span>
The genetic basis of tropical calcific pancreatitis (TCP) is different and is explained by mutations in the pancreatic secretory trypsin inhibitor (SPINK1) gene. However, mutated SPINK1 does not account for the disease in all the patients, neither does it explain the phenotypic heterogeneity between TCP and fibro-calculous pancreatic diabetes (FCPD). Recent studies suggest a crucial role for pancreatic renin-angiotensin system during chronic hypoxia in acute pancreatitis and for angiotensin converting enzyme (ACE) inhibitors in reducing pancreatic fibrosis in experimental models. We investigated the association of ACE gene insertion/deletion (I/D) polymorphism in TCP patients using a case-control approach. Since SPINK1 mutations are proposed a modifier role, we also investigated its interaction with the ACE gene variant.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 40 44 40 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 117 125 <span type="species:ncbi:9606">patients</span>
We analyzed the I/D polymorphism in the ACE gene (g.11417_11704del287) in 171 subjects comprising 91 TCP and 80 FCPD patients and compared the allelic and genotypic frequency in them with 99 healthy ethnically matched control subjects.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 290 294 290 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 399 406 399 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1 </italic>
###xml 28 36 <span type="species:ncbi:9606">patients</span>
###xml 60 68 <span type="species:ncbi:9606">patients</span>
###xml 242 250 <span type="species:ncbi:9606">patients</span>
###xml 424 432 <span type="species:ncbi:9606">patients</span>
We found 46% and 21% of TCP patients, 56% and 19.6% of FCPD patients and 54.5% and 19.2% of the healthy controls carrying the I/D and D/D genotypes respectively (P>0.05). No significant difference in the clinical picture was observed between patients with and without the del allele at the ACE in/del polymorphism in both categories. No association was observed with the presence or absence of N34S SPINK1 mutation in these patients.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
We conclude that the ACE insertion/deletion variant does not show any significant association with the pathogenesis, fibrosis and progression of tropical calcific pancreatitis and the fibro-calculous pancreatic diabetes.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 273 274 273 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 275 276 275 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 538 539 538 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 759 760 759 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 867 872 867 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRSS1</italic>
###xml 972 979 972 979 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1 </italic>
###xml 1085 1086 1085 1086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1087 1088 1087 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1225 1226 1225 1226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1006 1014 <span type="species:ncbi:9606">patients</span>
###xml 1198 1206 <span type="species:ncbi:9606">patients</span>
Chronic Pancreatitis (CP) is a major health care problem worldwide and is associated with varied etiologies. CP is identified clinically by loss of endocrine and/or exocrine functions and pathologically by the presence of chronic inflammation and fibrosis of the pancreas [1,2]. Tropical calcific pancreatitis (TCP) is a form of chronic pancreatitis of unknown etiology, more prevalent in the tropical regions of developing countries such as India whereas fibrocalculous pancreatic diabetes (FCPD) is a form of diabetes secondary to TCP [3]. Both TCP and FCPD are associated with extensive fibrosis involving both intra and inter-lobular regions and not limited to one zone of the pancreas, although the extent of fibrosis varies and is usually more in FCPD [4]. We and several others previously demonstrated an absence of mutations in the cationic trypsinogen gene (PRSS1) and a higher frequency of N34S mutation in the pancreatic secretory trypsin inhibitor (encoded by SPINK1 gene) in both FCPD and TCP patients without diabetes mellitus suggesting a common genetic basis for them [5,6]. However, other genetic and/or environmental factors may explain the phenotypic variability in FCPD and TCP patients without diabetes [5].
###end p 11
###begin p 12
###xml 160 161 160 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 326 327 326 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 328 329 328 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 455 457 455 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 567 569 567 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 570 572 570 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 740 742 740 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 861 863 861 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 864 866 864 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1083 1085 1083 1085 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1086 1088 1086 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1147 1149 1147 1149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1256 1258 1256 1258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1403 1405 1403 1405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1599 1601 1599 1601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1248 1254 <span type="species:ncbi:9606">humans</span>
###xml 1593 1597 <span type="species:ncbi:10116">rats</span>
The renin-angiotensin system (RAS) plays a central role in health and disease by maintaining the electrolyte and fluid balance and in turn, the blood pressure [7]. Apart from circulating RAS, several studies suggest the existence of local RAS components in tissues such as brain, heart, kidney, pancreas, adrenals and gonads [8,9]. Tissue specific RAS can act locally as paracrine and/or autocrine factors in meeting specific needs of individual tissues [10] and any functional alterations may be associated with pathophysiology of respective tissue/organ functions [11-13]. An intrinsic renin-angiotensin system (RAS) is present in the pancreas. Angiotensin converting enzyme (ACE), a zinc metallopeptidase is a key enzyme of this system [14]. ACE and RAS activity is known to be enhanced during acute pancreatitis and chronic hypoxia in experimental animals [15,16]. ACE cleaves angiotensin (AT)-I to AT-II, which induces proliferation of hepatic stellate cells (HSCs) and synthesis of extracellular matrix proteins by increasing the expression of transforming growth factor-beta [17,18]. Isolated pancreatic stellate cells are similar to HSCs [19] and known to be involved in pathogenesis of pancreatic fibrosis in both experimental animals and humans [20]. Increased accumulation of extra-cellular matrix is a histological characteristic of chronic pancreatitis that results in pancreatic fibrosis [21]. In addition, ACE inhibitors have recently been demonstrated to attenuate pancreatic inflammation and fibrosis in spontaneously occurring chronic pancreatitis in male Wistar Bonn/Kobori rats [22].
###end p 12
###begin p 13
###xml 61 65 61 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 397 399 397 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 400 402 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 411 415 411 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 678 682 678 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 855 857 855 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 895 899 895 899 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 1056 1063 1056 1063 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1 </italic>
###xml 1196 1200 1196 1200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 305 313 <span type="species:ncbi:9606">patients</span>
###xml 344 352 <span type="species:ncbi:9606">patients</span>
###xml 845 853 <span type="species:ncbi:9606">patients</span>
###xml 928 936 <span type="species:ncbi:9606">patients</span>
###xml 971 979 <span type="species:ncbi:9606">patients</span>
A polymorphism within intron 16 (g.11417_11704del287) of the ACE gene is strongly related to the circulating enzyme levels in a dose dependent manner [23]. The DD genotype that is associated with higher levels of circulating ACE than the II and ID genotypes, is known to be significantly more frequent in patients with myocardial infarction or patients with diabetic proteinuria than in controls [24,25]. Thus, ACE gene polymorphisms may play a role in the pathogenesis of chronic pancreatitis and several other pancreatic diseases including acute pancreatitis, pancreatic cancer, diabetes mellitus and cystic fibrosis. Although a recent study failed to find any association of ACE I/D polymorphism in familial and sporadic chronic pancreatitis, we hypothesized a role for this polymorphism in view of the extensive fibrosis observed in the TCP patients [26]. In this study, we investigated the ACE gene I/D polymorphism in TCP patients (without diabetes mellitus), FCPD patients and healthy controls to understand its association with the disease. Since, SPINK1 mutations are proposed to play a modifier role, we also investigated whether any association exists with the I/D polymorphism in the ACE gene.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and controls
###end title 15
###begin p 16
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 634 635 634 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 25 33 <span type="species:ncbi:9606">patients</span>
###xml 80 88 <span type="species:ncbi:9606">patients</span>
###xml 409 417 <span type="species:ncbi:9606">patients</span>
###xml 646 654 <span type="species:ncbi:9606">patients</span>
###xml 1017 1022 <span type="species:ncbi:9606">human</span>
A total of 171 unrelated patients (120 M+51 F) comprising of 91 TCP and 80 FCPD patients were recruited in the study based on the WHO criteria [27]. 99 unrelated ethnically matched individuals with complaints of dyspepsia were recruited as controls after a similar set of investigations excluded the disease in them. These individuals filled the same questionnaire and underwent similar investigations as the patients especially the imaging procedures which included computed tomography, endoscopic ultrasonography, magnetic resonance cholangio-pancreatography and endoscopic retrograde cholangio-pancreatography, wherever indicated [5]. All the patients and healthy controls were explained the purpose of the study and the complications of investigative procedures and peripheral blood samples were collected after they signed the written informed consent. The study was approved by the institutional ethics committee of respective institutes following the Indian Council of Medical Research guidelines for handling human samples.
###end p 16
###begin title 17
Genetic analysis
###end title 17
###begin p 18
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 201 205 201 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 907 908 877 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1080 1087 1050 1057 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1 </italic>
###xml 1124 1126 1094 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1330 1331 1300 1301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
Genomic DNA was isolated from peripheral blood leucocytes following standard protocols [28]. The genotype at I/D variant was determined by PCR amplification of genomic DNA fragment in intron 16 of the ACE gene using forward and reverse primers, 5'-CCACTCCCATCCTTTCTCC-3' and 5'-GGCCATCACATTCGTCAGA-3' respectively. The position of the amplified region in the gene covering the polymorphism was 11417-11595 (as per NT_010783). PCR was performed using cycling conditions of initial denaturation at 94degreesC for 3 min, followed by 35 cycles of denaturation at 94degreesC for 1 min, annealing at 59degreesC for 1 min and extension at 72degreesC for 1 min 30 sec, with a final 5 min extension at 72degreesC. PCR products of approximate 179 bp (without insertion) and approximate 466 bp (with 287 bp insertion) were detected by electrophoresis on a 2% agarose-gel containing ethidium bromide as shown in figure 1. Genotyping was repeated if any ambiguity was noted in the observations. The primer sequences and PCR conditions for analysis of the promoter region and four exons of the SPINK1 gene were selected from Witt et al. [29]. All the exons were sequenced individually on both the strands using internal sequencing primers and Big dye terminator cycle sequencing ready kit and an ABI 3730 Genetic Analyzer (Applied Biosystems) [5]. 10% of randomly selected samples were sequenced to confirm the genotypes.
###end p 18
###begin title 19
Statistical analysis
###end title 19
###begin p 20
###xml 262 269 262 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1 </italic>
###xml 678 682 678 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 745 747 738 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 128 136 <span type="species:ncbi:9606">patients</span>
Allele frequency was calculated by the allele counting method, which was then utilized to determine the genotype frequency. The patients were divided into TCP and FCPD based on the presence or absence of diabetes mellitus and further based on the status of N34S SPINK1 mutation and ACE in/del polymorphism. Statistical comparisons were carried out by using Pearson's Chi-squared test, unpaired t-test and odds ratios (OR) along with the 95% confidence interval (CI). Two-tailed P values less than 0.05 were considered statistically significant. Post-hoc power analysis showed the study being adequately powered (84.6%) to accept the null hypothesis that the I/D polymorphism in ACE gene is not associated with TCP (alpha = 0.05, beta = -1.426) [30].
###end p 20
###begin title 21
Results and discussion
###end title 21
###begin p 22
###xml 256 257 256 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 319 323 319 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
Tropical calcific pancreatitis is a form of chronic pancreatitis associated with fibrosis and pancreatic calcification. FCPD, a form of diabetes secondary to TCP, is thought to occur due to pancreatic destruction as a result of fibrosis and calcification [3]. We investigated the association of I/D polymorphism in the ACE gene with TCP and the phenotype of diabetes in FCPD.
###end p 22
###begin p 23
###xml 319 320 319 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 461 462 461 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 463 465 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 57 65 <span type="species:ncbi:9606">patients</span>
###xml 178 186 <span type="species:ncbi:9606">patients</span>
The median age at onset and age at presentation for FCPD patients was 32.6 yrs (95% CI 29.6-35.6) and 40.9 yrs (95% CI 37.8-44.0), which is significantly higher than that of TCP patients without diabetes mellitus [(25.8 yrs, 95% CI 23.5-28.1, P = 0.004) and (33.9 yrs, 95% CI 31.6-36.2, P = 0.001) respectively] (table 1). However, the duration of disease was similar in either category. As suggested earlier, FCPD represents a late stage manifestation of TCP [5,31].
###end p 23
###begin p 24
###xml 136 140 136 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 315 316 315 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 414 421 414 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1 </italic>
###xml 473 474 473 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 475 476 475 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 522 526 522 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 626 629 626 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE</italic>
###xml 777 778 777 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 787 788 787 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 937 944 937 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1 </italic>
###xml 1143 1150 1143 1150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1 </italic>
###xml 1269 1276 1269 1276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1 </italic>
###xml 1386 1392 1386 1392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1</italic>
###xml 1522 1529 1522 1529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1 </italic>
###xml 1605 1609 1605 1609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 1719 1726 1719 1726 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1 </italic>
###xml 1806 1810 1806 1810 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 1844 1851 1844 1851 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1 </italic>
###xml 154 162 <span type="species:ncbi:9606">patients</span>
###xml 250 258 <span type="species:ncbi:9606">patients</span>
###xml 463 471 <span type="species:ncbi:9606">patients</span>
###xml 870 878 <span type="species:ncbi:9606">patients</span>
###xml 1035 1043 <span type="species:ncbi:9606">patients</span>
###xml 1220 1227 <span type="species:ncbi:9606">patient</span>
###xml 1308 1315 <span type="species:ncbi:9606">patient</span>
###xml 1360 1368 <span type="species:ncbi:9606">patients</span>
###xml 1403 1411 <span type="species:ncbi:9606">patients</span>
###xml 1500 1508 <span type="species:ncbi:9606">patients</span>
###xml 1672 1680 <span type="species:ncbi:9606">patients</span>
###xml 1878 1886 <span type="species:ncbi:9606">patients</span>
We did not observe any significant difference either in the allele frequency or in the genotype distribution of the I/D polymorphism at ACE locus between patients and controls (D allele frequency; 0.46 and 0.47 respectively) and between TCP and FCPD patients (D allele frequency; 0.44 and 0.48 respectively) (table 2). No deviation from Hardy-Weinberg equilibrium was observed (P>0.05). Since frequency of mutated SPINK1 is reported to be similar in TCP and FCPD patients [5,6], we investigated whether the I/D variant in ACE gene can explain the phenotypic variability between them. We did not observe any association of the ACE I/D polymorphism with various phenotypic features including the age of onset and age of presentation, pancreatic calcification or surgeries (table 3). Table 4 summarizes the allele frequency and genotype distribution of I/D polymorphism in patients and the controls based on the presence or absence of N34S SPINK1 mutation (irrespective of their zygosity, heterozygous or homozygous genotypes). Of 91 TCP patients, 60 carried the wild type allele while 31 (34%) had at least one copy of the mutant allele at N34S SPINK1 variant. Genotypic distribution of the I/D variant was similar in the patient groups with and without N34S mutation in SPINK1 gene as well as in TCP and FCPD patient group and the normal individuals. Among TCP patients carrying mutated SPINK1, 15 (48%) patients were heterozygous for I/D ACE variant and 5 (16%) carried the DD genotype whereas of 41 patients without N34S SPINK1 mutation, 27 (45%) had I/D genotype and 14 (23%) carried DD genotype at the ACE locus. Similar observations were made for the group of 80 FCPD patients with and without N34S mutation in the SPINK1 gene. This suggests that there is no interaction between the I/D variant in the ACE gene and the N34S mutation in the SPINK1 gene in either TCP or FCPD patients. It may be interesting to investigate whether other variants in the ACE gene or any specific haplotype may explain the role of ACE in TCP and FCPD.
###end p 24
###begin p 25
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 521 522 521 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 656 658 656 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 659 661 659 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 763 765 763 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 914 916 914 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1212 1214 1212 1214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1336 1343 1336 1343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1 </italic>
###xml 1201 1204 <span type="species:ncbi:59530">Kob</span>
###xml 1206 1210 <span type="species:ncbi:10116">rats</span>
###xml 1306 1314 <span type="species:ncbi:9606">patients</span>
Angiotensin converting enzyme catalyzes the conversion of angiotensin I into the vasoactive and aldosterone-stimulating peptide angiotensin II [14], which carries out its biological functions by binding to two receptors, AT1R and AT2R [32]. Several studies have suggested the presence of a pancreatic RAS, having physiological effects via a paracrine/autocrine pattern in the exocrine and endocrine pancreas, probably in the regulation of pancreatic microcirculation, ductal anion secretion and islet hormonal secretion [9]. Both circulating and intrinsic pancreatic ACE activity is markedly elevated during acute and chronic inflammation of the pancreas [15,16]. Recent studies have shown that ACE enzyme directs pancreatic fibrogenesis in experimental animals [33] and inhibition of the RAS system with an ACE inhibitor attenuates pancreatic inflammation and fibrosis in an animal model of chronic pancreatitis [22]. Thus, angiotensinogen-II converted endogenously from angiotensinogen-I by circulating ACE may be directly involved in the induction of pancreatic inflammation and development of pancreatic fibrosis in the spontaneously occurring chronic pancreatitis in male Wistar Bonn/Kobori (WBN/Kob) rats [22]. However, our study failed to observe any association between I/D variant and TCP or FCPD patients irrespective of N34S SPINK1 mutation status.
###end p 25
###begin p 26
###xml 168 172 168 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 349 350 349 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 616 618 616 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 627 631 627 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 1061 1065 1061 1065 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 97 105 <span type="species:ncbi:9606">patients</span>
###xml 920 928 <span type="species:ncbi:9606">patients</span>
Our results are in agreement with the recent study on familial and sporadic chronic pancreatitis patients, which showed that the insertion/deletion polymorphism in the ACE gene does not make a significant contribution to the pathogenesis and progression of the disease [26]. Although, recent evidence suggests that TCP is a specific genetic entity [5], there may be certain overlapping features with idiopathic chronic pancreatitis (ICP). In fact, the nomenclature of idiopathic chronic pancreatitis is itself a matter of debate since genetic etiology appears to play an important role in both ICP and TCP in India [34]. Thus, ACE I/D polymorphism may not contribute to the pathogenesis of TCP despite the fact that the RAS system specifically affects the pancreas, an indication that local effects are more important than the systemic ones in pancreatic diseases. In the absence of intra-pancreatic ACE levels in these patients, there may exist a possibility that in contrast to other tissues such as heart and renal tissue, DD genotype does not influence the ACE gene expression and consequently its levels in the pancreas.
###end p 26
###begin title 27
Conclusion
###end title 27
###begin p 28
###xml 60 64 60 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 230 235 230 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 300 308 <span type="species:ncbi:9606">patients</span>
We conclude that the insertion/deletion polymorphism at the ACE locus does not play any role in the causation and progression of TCP. Further studies focusing on other environmental and/or genetic factors such as mutations in the CFTR gene may explain the phenotypic variability between TCP and FCPD patients.
###end p 28
###begin title 29
Abbreviations
###end title 29
###begin p 30
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
ACE Angiotensin converting enzyme
###end p 30
###begin p 31
AT Angiotensin
###end p 31
###begin p 32
CP Chronic pancreatitis
###end p 32
###begin p 33
CI Confidence interval
###end p 33
###begin p 34
FCPD Fibrocalculous pancreatic diabetes
###end p 34
###begin p 35
HSCs Hepatic stellate cells
###end p 35
###begin p 36
ICP Idiopathic chronic pancreatitis
###end p 36
###begin p 37
OR Odds ratio
###end p 37
###begin p 38
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRSS1 </italic>
PRSS1 Protease, serine, 1 (trypsin 1)
###end p 38
###begin p 39
RAS Renin-angiotensin system
###end p 39
###begin p 40
TCP Tropical calcific pancreatitis
###end p 40
###begin p 41
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1 </italic>
SPINK1 Serine protease inhibitor, Kazal type I
###end p 41
###begin p 42
WHO World Health Organization
###end p 42
###begin title 43
Competing interests
###end title 43
###begin p 44
The author(s) declare that they have no competing interests.
###end p 44
###begin title 45
Authors' contributions
###end title 45
###begin p 46
###xml 153 161 <span type="species:ncbi:9606">patients</span>
SB carried out the molecular genetic studies including sequencing analysis, DNR and GVR designed studies of the phenotypes, identified and diagnosed the patients, SM performed the statistical analysis, GRC conceptualized, designed the study and drafted the manuscript. All authors read and approved the final manuscript.
###end p 46
###begin title 47
Pre-publication history
###end title 47
###begin p 48
The pre-publication history for this paper can be accessed here:
###end p 48
###begin p 49

###end p 49
###begin title 50
Acknowledgements
###end title 50
###begin p 51
###xml 36 44 <span type="species:ncbi:9606">patients</span>
###xml 276 284 <span type="species:ncbi:9606">patients</span>
The authors are grateful to all the patients and the normal individuals for agreeing to participate in the study and particularly for giving consent for genetic studies. Thanks are also due to Dr Ramakrishna, Asian Institute of Gastroenterology for his help in recruitment of patients and collection of blood samples. The financial support of Council of Scientific and Industrial Research, Ministry of Science and Technology, Government of India is gratefully acknowledged.
###end p 51
###begin article-title 52
Natural history of chronic pancreatitis
###end article-title 52
###begin article-title 53
Chronic pancreatitis
###end article-title 53
###begin article-title 54
Familial aggregation in tropical fibrocalculous pancreatic diabetes
###end article-title 54
###begin article-title 55
Pancreatic pathology in pancreatic calcification with diabetes
###end article-title 55
###begin article-title 56
###xml 62 73 62 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PSTI/SPINK1</italic>
###xml 118 123 118 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRSS1</italic>
Mutations in the pancreatic secretory trypsin inhibitor gene (PSTI/SPINK1) rather than the cationic trypsinogen gene (PRSS1) are significantly associated with tropical calcific pancreatitis
###end article-title 56
###begin article-title 57
SPINK1 is a susceptibility gene for fibrocalculous pancreatic diabetes in subjects from Indian subcontinent
###end article-title 57
###begin article-title 58
The renin-angiotensin system and its receptors
###end article-title 58
###begin article-title 59
Circulating and tissue angiotensin systems
###end article-title 59
###begin article-title 60
Tissue renin-angiotensin system: its expression, localization, regulation and potential role in the pancreas
###end article-title 60
###begin article-title 61
Levels of angiotensin and molecular biology of the tissue renin angiotensin systems
###end article-title 61
###begin article-title 62
Molecular mechanisms of angiotensin II-induced vascular injury
###end article-title 62
###begin article-title 63
###xml 56 61 <span type="species:ncbi:9606">human</span>
Angiotensin II induces contraction and proliferation of human hepatic stellate cells
###end article-title 63
###begin article-title 64
###xml 32 37 <span type="species:ncbi:9606">human</span>
Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor
###end article-title 64
###begin article-title 65
The angiotensin I-converting enzyme
###end article-title 65
###begin article-title 66
Changes of angiotensin-converting enzyme activity in the pancreas of chronic hypoxia and acute pancreatitis
###end article-title 66
###begin article-title 67
Regulated expression of pancreatic renin angiotensin system in experimental pancreatitis
###end article-title 67
###begin article-title 68
Molecular regulation of hepatic fibrosis, an integrated response to injury
###end article-title 68
###begin article-title 69
###xml 14 17 <span type="species:ncbi:10116">rat</span>
Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta
###end article-title 69
###begin article-title 70
###xml 78 81 <span type="species:ncbi:10116">rat</span>
Identification of mediators stimulating proliferation and matrix synthesis of rat pancreatic stellate cells
###end article-title 70
###begin article-title 71
Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis
###end article-title 71
###begin article-title 72
###xml 43 48 <span type="species:ncbi:9606">human</span>
Activation of pancreatic stellate cells in human and experimental pancreatic fibrosis
###end article-title 72
###begin article-title 73
###xml 99 103 <span type="species:ncbi:10116">rats</span>
Angiotensin- Converting Enzyme attenuates pancreatic inflammation and fibrosis in male Bonn/Kabori rats
###end article-title 73
###begin article-title 74
An insertion/deletion polymorphism in angiotensin converting enzyme gene accounting for half the variance of serum enzyme levels
###end article-title 74
###begin article-title 75
Deletion polymorphism in the gene for angiotensin converting enzyme is a potent risk factor for myocardial infarction
###end article-title 75
###begin article-title 76
###xml 83 91 <span type="species:ncbi:9606">patients</span>
Association between ACE gene polymorphism and diabetic nephropathy in South Indian patients
###end article-title 76
###begin article-title 77
The functional angiotensin converting enzyme gene I/D polymorphism does not alter susceptibility to chronic pancreatitis
###end article-title 77
###begin article-title 78
###xml 53 58 <span type="species:ncbi:9606">human</span>
Simple salting out procedure for extracting DNA from human nucleated cells
###end article-title 78
###begin article-title 79
Mutations in the gene encoding the serine protease inhibitor, Kazal type1 are associated with chronic pancreatitis
###end article-title 79
###begin article-title 80
Power and Replication in Case-Control Studies
###end article-title 80
###begin article-title 81
Natural history of endocrine failure in tropical chronic pancreatitis: a longitudinal follow-up study
###end article-title 81
###begin article-title 82
Angiotensin II elicited signal transduction via AT-1 receptors in endothelial cells
###end article-title 82
###begin article-title 83
###xml 115 119 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Angiotensin II type 1 receptor interaction is an important regulator for the development of pancreatic fibrosis in mice
###end article-title 83
###begin article-title 84
###xml 11 17 11 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRSS1 </italic>
###xml 46 53 46 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1 </italic>
Absence of PRSS1 mutations and association of SPINK1 trypsin inhibitor mutations in hereditary and non-hereditary chronic pancreatitis
###end article-title 84
###begin title 85
Figures and Tables
###end title 85
###begin p 86
###xml 76 80 76 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
Agarose gel electrophoresis showing genotypes at in/del polymorphism in the ACE gene (g.11417_11704del287). Lanes 1 & 13 represent DNA marker XIV (New England Biolabs, USA) and marker V (Boerhinger Manheim, Germany), Lane 2:Control for genotype ID, Lane 3:Control for genotype II, Lane 4:Control for genotype DD. Lanes 5, 8, 10 show II genotype, lanes 7 and 12 are ID genotypes and lanes 6, 9, 11 carry the DD genotype. bp, base-pair
###end p 86
###begin p 87
Characteristics of the study population
###end p 87
###begin p 88
###xml 13 21 <span type="species:ncbi:9606">patients</span>
n, number of patients; yrs, years; TCP, tropical calcific pancreatitis; FCPD, fibro-calculous pancreatic diabetes
###end p 88
###begin p 89
NA, not applicable; Figures are quoted as median, range 95% CI
###end p 89
###begin p 90
###xml 83 91 <span type="species:ncbi:9606">patients</span>
Allele frequency and genotype distribution of I/D polymorphism at ACE locus in TCP patients & control subjects
###end p 90
###begin p 91
n, number of individuals; TCP, tropical calcific pancreatitis; FCPD, fibro-calculous pancreatic diabetes; ACE, angiotensin converting enzyme; I/D, insertion/deletion polymorphism at ACE locus figures in parentheses indicate number of individuals; P values are represented on comparison of TCP with FCPD, TCP with controls and FCPD with controls.
###end p 91
###begin p 92
###xml 34 42 <span type="species:ncbi:9606">patients</span>
Clinical features of TCP and FCPD patients grouped according to their genotype at in/del polymorphism at ACE gene
###end p 92
###begin p 93
n, number of individuals; TCP, tropical calcific pancreatitis; FCPD, fibro-calculous pancreatic diabetes; ACE, angiotensin converting enzyme
###end p 93
###begin p 94
I/D, insertion/deletion polymorphism at ACE locus; NA, not applicable; figures in parentheses indicate percentage; figures are quoted as mean +/- SD
###end p 94
###begin p 95
###xml 87 95 <span type="species:ncbi:9606">patients</span>
P values are represented on comparison of II vs ID+DD genotypes in TCP, FCPD and total patients
###end p 95
###begin p 96
###xml 83 91 <span type="species:ncbi:9606">patients</span>
Allele frequency and genotype distribution of I/D polymorphism at ACE locus in TCP patients and controls based on their N34S SPINK1 status
###end p 96
###begin p 97
###xml 346 354 <span type="species:ncbi:9606">patients</span>
n, number of individuals; TCP, tropical calcific pancreatitis; FCPD, fibro-calculous pancreatic diabetes; ACE, angiotensin converting enzyme; I/D, insertion/deletion polymorphism at ACE locus figures in parentheses indicate number of individuals; P value is represented on comparison of N34S SPINK1 positive vs. N34S negative TCP, FCPD and total patients.
###end p 97
###begin p 98
*, includes 9 N34S SPINK1 homozygotes and 22 heterozygotes; # includes 4 N34S SPINK1 homozygotes and 17 heterozygotes, $, includes 3 N34S SPINK1 heterozygotes
###end p 98

